Obeticholic acid for the treatment of nonalcoholic steatohepatitis
INTRODUCTION: NAFLD has grown to become the most prevalent liver disease in the world, with a quarter of the general population estimated to have the disease. NASH, characterized as NAFLD with inflammation, is associated with worsening fibrosis along with increased incidence of HCC. Despite high prevalence of this disease, no pharmacologic treatments approved by regulatory agencies are available.
AREAS COVERED: This review briefly discusses present understanding of NASH pathology and currently available treatments. We also discuss data on the role of OCA as an FXR agonist in modulating disease in NASH. A comprehensive literature search of review articles, original research articles, and prospective clinical trials from 1998 to the present was performed.
EXPERT OPINION: Based on 18-month interim findings of the REGENERATE trial, OCA likely improves fibrosis in NASH and therefore may have a beneficial effect in delaying or even preventing cirrhosis. The side effect of an atherogenic lipoprotein profile may adversely affect long-term outcomes, though studies have shown that co-administration of statins is able to mitigate this effect. OCA is likely to become an option for treatment, but the specific context within which it may be prescribed still needs to be clarified.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Expert review of gastroenterology & hepatology - 14(2020), 5 vom: 31. Mai, Seite 311-321 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shah, Raj A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.04.2021 Date Revised 14.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/17474124.2020.1748498 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308266714 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308266714 | ||
| 003 | DE-627 | ||
| 005 | 20231225131353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17474124.2020.1748498 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1027.xml |
| 035 | |a (DE-627)NLM308266714 | ||
| 035 | |a (NLM)32241197 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shah, Raj A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Obeticholic acid for the treatment of nonalcoholic steatohepatitis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.04.2021 | ||
| 500 | |a Date Revised 14.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: NAFLD has grown to become the most prevalent liver disease in the world, with a quarter of the general population estimated to have the disease. NASH, characterized as NAFLD with inflammation, is associated with worsening fibrosis along with increased incidence of HCC. Despite high prevalence of this disease, no pharmacologic treatments approved by regulatory agencies are available | ||
| 520 | |a AREAS COVERED: This review briefly discusses present understanding of NASH pathology and currently available treatments. We also discuss data on the role of OCA as an FXR agonist in modulating disease in NASH. A comprehensive literature search of review articles, original research articles, and prospective clinical trials from 1998 to the present was performed | ||
| 520 | |a EXPERT OPINION: Based on 18-month interim findings of the REGENERATE trial, OCA likely improves fibrosis in NASH and therefore may have a beneficial effect in delaying or even preventing cirrhosis. The side effect of an atherogenic lipoprotein profile may adversely affect long-term outcomes, though studies have shown that co-administration of statins is able to mitigate this effect. OCA is likely to become an option for treatment, but the specific context within which it may be prescribed still needs to be clarified | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Nonalcoholic fatty liver disease | |
| 650 | 4 | |a farnesoid X receptor | |
| 650 | 4 | |a fibroblast growth factor 19 | |
| 650 | 4 | |a liver fibrosis | |
| 650 | 4 | |a nonalcoholic steatohepatitis | |
| 650 | 4 | |a obeticholic acid | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Gastrointestinal Agents |2 NLM | |
| 650 | 7 | |a Receptors, Cytoplasmic and Nuclear |2 NLM | |
| 650 | 7 | |a obeticholic acid |2 NLM | |
| 650 | 7 | |a 0462Z4S4OZ |2 NLM | |
| 650 | 7 | |a farnesoid X-activated receptor |2 NLM | |
| 650 | 7 | |a 0C5V0MRU6P |2 NLM | |
| 650 | 7 | |a Chenodeoxycholic Acid |2 NLM | |
| 650 | 7 | |a 0GEI24LG0J |2 NLM | |
| 700 | 1 | |a Kowdley, Kris V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of gastroenterology & hepatology |d 2007 |g 14(2020), 5 vom: 31. Mai, Seite 311-321 |w (DE-627)NLM185080200 |x 1747-4132 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2020 |g number:5 |g day:31 |g month:05 |g pages:311-321 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/17474124.2020.1748498 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2020 |e 5 |b 31 |c 05 |h 311-321 | ||